| |
| |
|
| Insider
Information: |
Goodman Corey S |
| Relationship: |
|
| City: |
South San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
8 |
|
| Direct
Shares |
12,296,786 |
|
|
Indirect Shares
|
8,829,949 |
|
|
| Direct
Value |
$340,131,503 |
|
|
|
Indirect Value
|
$53,489,518 |
|
|
| Total
Shares |
21,126,735 |
|
|
| Total
Value |
$393,621,021 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
1
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
1
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
-1.0
|
0.0
|
| Percentage
Gain/Loss : |
 -27.8%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Renovis Inc |
RNVS |
Director |
2008-05-02 |
0 |
2008-05-02 |
0 |
Premium* |
|
|
Pfizer Inc |
PFE |
Senior Vice President |
2009-02-26 |
82,232 |
2009-02-26 |
1,095 |
Premium* |
|
|
Precision Biosciences Inc |
DTIL |
10% Owner |
2019-04-01 |
0 |
2019-04-01 |
4,265,141 |
Premium* |
|
|
Akero Therapeutics, Inc. |
AKRO |
|
2019-06-24 |
0 |
2020-07-06 |
3,033,552 |
Premium* |
|
|
Alx Oncology Holdings Inc |
ALXO |
Executive Chairman, Di... |
|
0 |
2020-07-21 |
515,894 |
Premium* |
|
|
Metacrine, Inc. |
MTCR |
|
2020-09-18 |
3,059,123 |
2020-09-18 |
0 |
Premium* |
|
|
Ventyx Biosciences, Inc. |
VTYX |
See Remarks, 10% Owner |
2021-10-25 |
3,997,269 |
2021-10-25 |
1,014,267 |
Premium* |
|
|
Rayzebio, Inc. |
RYZB |
|
2023-09-19 |
5,158,162 |
2023-09-19 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| RYZB |
Rayzebio, Inc. |
|
• • • |
2023-09-19 |
4 |
A |
$0.00 |
$0 |
D/D |
5,158,162 |
5,158,162 |
0 |
- |
|
| VTYX |
Ventyx Biosciences, Inc. |
See Remarks |
– – • |
2021-10-25 |
4 |
B |
$16.00 |
$5,000,000 |
D/D |
312,500 |
3,997,269 |
2.45 |
% |
|
| VTYX |
Ventyx Biosciences, Inc. |
See Remarks |
– – • |
2021-10-25 |
4 |
A |
$0.00 |
$0 |
D/D |
3,684,769 |
3,684,769 |
0 |
- |
|
| VTYX |
Ventyx Biosciences, Inc. |
10% Owner |
– – • |
2021-10-20 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,014,267 |
|
- |
|
| MTCR |
Metacrine, Inc. |
See Remarks |
• • • |
2020-09-18 |
4 |
B |
$13.00 |
$2,990,000 |
D/D |
230,000 |
230,000 |
0.01 |
- |
|
| MTCR |
Metacrine, Inc. |
See Remarks |
• • • |
2020-09-18 |
4 |
A |
$0.00 |
$0 |
D/D |
2,829,123 |
3,059,123 |
0 |
- |
|
| ALXO |
Alx Oncology Holdings Inc |
Executive Chairman |
– • • |
2020-07-21 |
4 |
A |
$0.00 |
$0 |
I/I |
7,188,585 |
54,083 |
0 |
- |
|
| ALXO |
Alx Oncology Holdings Inc |
Executive Chairman |
– • • |
2020-07-21 |
4 |
B |
$19.00 |
$16,150,000 |
I/I |
850,000 |
850,000 |
2.25 |
- |
|
| ALXO |
Alx Oncology Holdings Inc |
Director |
– • • |
2020-07-16 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
461,962 |
|
- |
|
| AKRO |
Akero Therapeutics, Inc. |
|
• • • |
2020-07-06 |
4 |
S |
$33.83 |
$155,721 |
I/I |
(4,603) |
3,033,552 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
|
• • • |
2020-07-02 |
4 |
S |
$33.63 |
$127,805 |
I/I |
(3,800) |
3,038,155 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
|
• • • |
2020-07-01 |
4 |
S |
$34.45 |
$3,723,010 |
I/I |
(108,064) |
3,041,955 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
10% Owner |
– – • |
2020-03-06 |
4 |
S |
$23.79 |
$42,831 |
I/I |
(1,800) |
3,150,019 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
10% Owner |
– – • |
2020-03-05 |
4 |
S |
$23.53 |
$200,011 |
I/I |
(8,500) |
3,151,819 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
10% Owner |
– – • |
2020-03-04 |
4 |
S |
$23.81 |
$848,766 |
I/I |
(35,650) |
3,160,319 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
10% Owner |
– – • |
2020-03-03 |
4 |
S |
$23.00 |
$147,199 |
I/I |
(6,401) |
3,195,969 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
10% Owner |
– – • |
2020-03-02 |
4 |
S |
$23.06 |
$237,459 |
I/I |
(10,297) |
3,202,370 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
10% Owner |
– – • |
2020-02-28 |
4 |
S |
$21.30 |
$108,652 |
I/I |
(5,100) |
3,212,667 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
10% Owner |
– – • |
2020-02-27 |
4 |
S |
$22.54 |
$40,144 |
I/I |
(1,781) |
3,227,767 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
10% Owner |
– – • |
2020-02-26 |
4 |
S |
$22.44 |
$56,615 |
I/I |
(2,523) |
3,229,548 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
10% Owner |
– – • |
2020-02-25 |
4 |
S |
$23.67 |
$37,876 |
I/I |
(1,600) |
3,232,071 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
10% Owner |
– – • |
2020-02-12 |
4 |
S |
$27.14 |
$163 |
I/I |
(6) |
3,233,671 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
10% Owner |
– – • |
2020-02-11 |
4 |
S |
$27.05 |
$59,068 |
I/I |
(2,184) |
3,233,677 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
10% Owner |
– – • |
2020-02-10 |
4 |
S |
$27.08 |
$212,168 |
I/I |
(7,836) |
3,225,861 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
10% Owner |
– – • |
2020-02-06 |
4 |
S |
$27.03 |
$164,955 |
I/I |
(6,102) |
3,233,697 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
